logo

TRIB

Trinity Biotech·NASDAQ
--
--(--)
--
--(--)
1.94 / 10
Underperform

Fundamental metrics indicate weak status (1.9/10). Bullish considerations: Interest coverage ratio (EBIT / Interest expense) (%) and Net profit attributable to parent company shareholders / Net profit (%), however risks emerge in Net profit / Total profit (%) and ROA (%). Final rating: defensive.

Fundamental(1.94)SentimentTechnical

Analysis Checks(2/5)

ROA (%)
Value-14.55
Score1/3
Weight9.91%
1M Return-0.54%
Net profit attributable to parent company shareholders / Net profit (%)
Value100.00
Score2/3
Weight27.33%
1M Return-1.71%
Annualized net profit margin on total assets (%)
Value-29.10
Score1/3
Weight9.91%
1M Return-0.54%
Interest coverage ratio (EBIT / Interest expense) (%)
Value27.58
Score3/3
Weight11.06%
1M Return-0.59%
Net profit / Total profit (%)
Value102.07
Score1/3
Weight41.79%
1M Return-2.89%
Is TRIB fundamentally strong?
  • TRIB scores 1.94/10 on fundamentals and holds a Premium valuation at present. Backed by its 0.00% ROE, -73.83% net margin, -0.41 P/E ratio, -0.30 P/B ratio, and 39.76% earnings growth, these metrics solidify its Underperform investment rating.